Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCV-LITE
- Development stage
- Phase 1
- Lead developer
- LiteVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PCV-LITE is a novel pneumococcal conjugate vaccine developed by LiteVax BV. It is a fractional dose of a pneumococcal polysaccharide conjugate vaccine, designed to broaden protection against *Streptococcus pneumoniae*. This bacterium is a major cause of serious infections including bloodstream infections, pneumonia, and meningitis. The specific PCV-LITE formulation mentioned in clinical trials is administered without the LiteVax Adjuvant, distinguishing it from other formulations that include the adjuvant.
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on PCV-LITE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCV-LITE.